Glucobay

Basic Glucobay information

• INN (international nonproprietary name): Acarbose
• Brand names available in the United Kingdom: Glucobay (tablets 50 mg, 100 mg)
• ATC code: A10BF01 (alpha‑glucosidase inhibitors)
• Forms and strengths: tablets 50 mg and 100 mg
• Manufacturers in the United Kingdom: Bayer (Glucobay)
• Registration status in the United Kingdom: Prescription-only medicine (POM)
• OTC / Rx classification: Prescription only (Rx)

Legal status and availability in the UK

In our online pharmacy, Glucobay is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.

Clinical effectiveness in the UK

Are people on the NHS seeing real benefit with acarbose for after‑meal sugar control?

Within NHS practice acarbose (marketed as Glucobay) is used as adjunctive therapy for Type 2 diabetes where post‑meal control is targeted.

Acarbose produces modest HbA1c improvements, with most benefit in those whose glucose excursions are diet‑responsive.

Adherence is the main limiting factor because frequent gastrointestinal side effects reduce persistence unless slow titration and dietary counselling are used.

Primary‑care prescribers tend to reserve acarbose for patients intolerant of first‑line agents or where reducing postprandial peaks is the clinical priority.

NHS pathways emphasise shared decision‑making, glucose monitoring and stepwise dose uptitration from 50 mg three times daily.

• Patient benefits: Targeted postprandial glucose lowering; modest HbA1c benefit when added to existing therapy; low systemic absorption.
• Patient challenges: Very common flatulence and abdominal pain affecting adherence; diarrhoea during titration; social embarrassment and difficulty recognising hypoglycaemia when combined with sulfonylureas or insulin.

Indications and expanded uses (MHRA, NHS and off‑label practice)

Wondering when a clinician might choose Glucobay over other diabetes medicines?

Licensed indication is treatment of Type 2 diabetes mellitus as an adjunct to diet and exercise; acarbose is an alpha‑glucosidase inhibitor (ATC A10BF01).

In the UK prescribing follows MHRA and NHS formularies and acarbose is issued as a prescription‑only medicine.

Off‑label or expanded uses sometimes seen in private clinics include management of impaired glucose tolerance and prevention of post‑bariatric hypoglycaemia, but evidence for these is limited.

Use is discouraged in Type 1 diabetes.

1. MHRA‑labelled indication: Adjunctive therapy for Type 2 diabetes mellitus.
2. Common off‑label scenarios: Impaired glucose tolerance; post‑bariatric hypoglycaemia prevention (clinician‑led, limited evidence).
3. Required governance for off‑label use: Document informed consent, record monitoring plan, and provide rationale in notes.

Composition and brand landscape (active ingredient, UK brands, generics)

Confused by brand names and strengths when your GP sends a prescription?

The active ingredient is acarbose (INN).

In the UK it is available as Glucobay (Bayer) and as generic acarbose.

Tablets come in 50 mg and 100 mg strengths; details should always be checked on the pack and patient information leaflet.

Classification: prescription-only medicine (POM).

Contraindications and special precautions (high‑risk groups)

Who should definitely not take Glucobay?

Absolute contraindications include hypersensitivity to acarbose or excipients, chronic intestinal diseases (inflammatory bowel disease, colonic ulceration, partial intestinal obstruction), conditions liable to deteriorate with abdominal distension, cirrhosis and severe renal impairment (creatinine clearance below 25 mL/min).

Relative precautions include known hepatic dysfunction or prior raised transaminases, and the elderly, who require closer monitoring.

Pregnancy and breastfeeding data are limited and specialist advice should be sought; avoid unless the expected benefit justifies potential risk.

• Absolute contraindications: Hypersensitivity; chronic intestinal disease; conditions worsened by abdominal distension; cirrhosis; creatinine clearance <25 mL/min.
• Relative precautions: Hepatic dysfunction/history of elevated transaminases; elderly.

Practical advice: counsel patients that severe GI upset may affect driving or social activities and that heavy alcohol can aggravate intolerance and complicate glycaemic control.

Dosage guidelines used in NHS practice (start, titration, special populations)

How should Glucobay be started so stomach symptoms are tolerable?

The standard adult regimen is to start 50 mg with the first bite of each main meal three times daily, and to titrate by tolerability to 100 mg three times daily.

The maximum authorised dose is 200 mg three times daily.

Children under 18 years: use not established.

Elderly patients: no routine dose reduction is required but monitor for gastrointestinal effects and hepatic enzyme changes.

Renal impairment: contraindicated in severe kidney dysfunction (creatinine clearance below 25 mL/min).

Missed dose: take at the next meal but do not double doses.

Overdose: mainly gastrointestinal symptoms; hypoglycaemia is rare unless used with other antidiabetics — treat hypoglycaemia with glucose (dextrose), not sucrose.

Interactions overview (drugs and foods)

What to avoid combining with Glucobay and how to treat low blood sugar if it happens?

Pharmacodynamic interactions are most important: combining acarbose with sulfonylureas or insulin increases the risk of hypoglycaemia.

If hypoglycaemia occurs it must be treated with pure glucose (dextrose) because acarbose blocks sucrose hydrolysis and ordinary table sugar will not correct the low effectively.

There are no major CYP‑mediated interactions documented; metformin and other oral agents are frequently used in combination in practice.

Food and timing: acarbose must be taken with the first bite of a meal for efficacy; large simple‑sugar loads will diminish benefit.

Alcohol may worsen gastrointestinal intolerance and add variability to glycaemic response.

GI complaints and occasional hepatic enzyme rises are the main reported adverse effects; clinicians should report suspected reactions via Yellow Card.

• Drug classes to monitor: Insulin; sulfonylureas; other glucose‑lowering agents.
• Food precautions: Take with first bite; avoid large simple sugar loads.
• Reporting: Report adverse events to MHRA Yellow Card if suspected.

Comparable medicines and NHS prescribing preferences

When might a clinician choose an alpha‑glucosidase inhibitor instead of other available diabetes drugs?

Acarbose shares its class with miglitol and voglibose, which have similar mechanisms but are not marketed in the UK.

The NHS usually favours metformin as first‑line therapy; acarbose typically becomes an alternative when postprandial control is the treatment priority or where other agents are contraindicated.

Advantages of acarbose include targeted postprandial efficacy and low systemic absorption.

Disadvantages are a high burden of gastrointestinal adverse events, monitoring needs for liver enzymes in at‑risk people, and limited evidence for weight loss or cardiovascular benefit compared with newer agents such as SGLT2 inhibitors and GLP‑1 receptor agonists.

1. When to choose acarbose: Postprandial hyperglycaemia predominates; metformin intolerance; patient wishes to avoid systemic drug exposure.
2. When to consider alternatives: Significant GI sensitivity, need for cardiovascular benefit, simpler dosing preferences, or preference for agents with proven weight loss.

FAQ — common NHS patient questions

Will Glucobay make me gain weight?

Unlikely; acarbose has minimal systemic absorption and is generally weight‑neutral compared with several other antidiabetics.

What should I do if I get severe wind or diarrhoea?

Contact your GP or pharmacist; slowing the titration or reducing the dose often improves symptoms and they usually improve over time.

If I become hypoglycaemic while on acarbose, what should I use?

Treat with pure glucose (dextrose) tablets or gel — do not rely on ordinary table sugar (sucrose) because acarbose impairs sucrose breakdown.

Can I buy Glucobay over the counter?

No — in the UK acarbose is a prescription‑only medicine, supplied on an NHS or private prescription.

Practical guidelines for proper use and pharmacist counselling (NHS style)

What should a pharmacist cover when dispensing Glucobay?

Confirm the diabetes diagnosis and review all concomitant antidiabetic medicines to assess hypoglycaemia risk.

Explain dosing clearly: start 50 mg three times daily with the first bite of each main meal, titrate to 100 mg three times daily as tolerated, maximum 200 mg three times daily.

Reinforce that tablets must be taken with meals for effect and that GI side effects are common, particularly flatulence and abdominal pain.

Advise on monitoring: baseline LFTs for at‑risk patients and periodic checks if symptoms or abnormal labs occur; avoid use in severe renal impairment.

Provide written patient information, supply guidance on carrying glucose (dextrose) for hypoglycaemia, and signpost NHS diabetes education, local clinics and the NHS App for repeat prescriptions.

Refer the patient to a GP or diabetes clinic if severe GI effects persist, if LFTs rise, or if there are recurrent hypoglycaemic episodes while on other glucose‑lowering drugs.

Delivery across the United Kingdom